Pancreatic cancer: understanding and overcoming chemoresistance

被引：280
作者：
Wang, Zhiwei [1 ]
Li, Yiwei [1 ]
Ahmad, Aamir [1 ]
Banerjee, Sanjeev [1 ]
Azmi, Asfar S. [1 ]
Kong, Dejuan [1 ]
Sarkar, Fazlul H. [1 ]
机构：
[1] Wayne State Univ, Dept Pathol, Karmanos Canc Inst, Sch Med,Hudson Webber Canc Res Ctr 740, Detroit, MI 48201 USA
来源：
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY | 2011年 / 8卷 / 01期
关键词：
EPITHELIAL-MESENCHYMAL TRANSITION; DRUG-RESISTANCE; SIDE POPULATION; CELL-LINES; STEM-CELLS; GEMCITABINE; MICRORNAS; SENSITIVITY; EXPRESSION; INVASION;
D O I：
10.1038/nrgastro.2010.188
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Pancreatic cancer is a highly aggressive malignancy. This feature is believed to be partly attributable to the chemotherapy-resistant characteristics of specific subgroups of pancreatic cancer cells, namely those with an epithelial-mesenchymal transition (EMT) phenotype and cancer stem cells. Accumulating evidence suggests that several new and emerging concepts might be important in the drug-resistant phenotype of these cell types. An understanding of the molecular mechanisms underlying drug resistance in patients with pancreatic cancer might help researchers to devise novel strategies to overcome such resistance. In particular, microRNAs (miRNAs) seem to be critical regulators of drug resistance in pancreatic cancer cells. Selective and targeted elimination of cells with an EMT phenotype and cancer stem cells could be achieved by regulating the expression of specific miRNAs.
引用
收藏
页码：27 / 33
页数：7
相关论文
共 59 条
[1]   RETRACTED: Gemcitabine Sensitivity Can Be Induced in Pancreatic Cancer Cells through Modulation of miR-200 and miR-21 Expression by Curcumin or Its Analogue CDF (Retracted article. See vol. 78, pg. 5466, 2018) [J].
Ali, Shadan ;
Ahmad, Aamir ;
Banerjee, Sanjeev ;
Padhye, Subhash ;
Dominiak, Kristin ;
Schaffert, Jacqueline M. ;
Wang, Zhiwei ;
Philip, Philip A. ;
Sarkar, Fazlul H. .
CANCER RESEARCH, 2010, 70 (09) :3606-3617
[2]   Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer [J].
Arumugam, Thiruvengadam ;
Ramachandran, Vijaya ;
Fournier, Keith F. ;
Wang, Huamin ;
Marquis, Lauren ;
Abbruzzese, James L. ;
Gallick, Gary E. ;
Logsdon, Craig D. ;
McConkey, David J. ;
Choi, Woonyoung .
CANCER RESEARCH, 2009, 69 (14) :5820-5828
[3]   INNOVATION Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications [J].
Brown, Brian D. ;
Naldini, Luigi .
NATURE REVIEWS GENETICS, 2009, 10 (08) :578-585
[4]   Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition [J].
Buck, Elizabeth ;
Eyzaguirre, Alexandra ;
Barr, Sharon ;
Thompson, Stuart ;
Sennello, Regina ;
Young, David ;
Iwata, Kenneth K. ;
Gibson, Neil W. ;
Cagnoni, Pablo ;
Haley, John D. .
MOLECULAR CANCER THERAPEUTICS, 2007, 6 (02) :532-541
[5]  
Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126
[6]   Integrins as Novel Drug Targets for Overcoming Innate Drug Resistance [J].
Damiano, Jason S. .
CURRENT CANCER DRUG TARGETS, 2002, 2 (01) :37-43
[7]   Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma [J].
Dembinski, Jennifer L. ;
Krauss, Stefan .
CLINICAL & EXPERIMENTAL METASTASIS, 2009, 26 (07) :611-623
[8]   Pancreatic Cancer Cells Resistant to Chemoradiotherapy Rich in "Stem-Cell-Like" Tumor Cells [J].
Du, Zhiyong ;
Qin, Renyi ;
Wei, Cuifeng ;
Wang, Min ;
Shi, Chengjian ;
Tian, Rui ;
Peng, Chenghong .
DIGESTIVE DISEASES AND SCIENCES, 2011, 56 (03) :741-750
[9]   The therapeutic promise of the cancer stem cell concept [J].
Frank, Natasha Y. ;
Schatton, Tobias ;
Frank, Markus H. .
JOURNAL OF CLINICAL INVESTIGATION, 2010, 120 (01) :41-50
[10]   Targeting microRNAs in cancer: rationale, strategies and challenges [J].
Garzon, Ramiro ;
Marcucci, Guido ;
Croce, Carlo M. .
NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (10) :775-789
123456